Innovations Enable Packaging to Play Many Roles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovations Enable Packaging to Play Many Roles
Drug packaging performs functions such as ensuring patient well-being, providing information, preventing tampering, blocking counterfeiting, and improving compliance. Since 1977, packaging innovations have occurred in four major categories. The author provides an overview of major packaging improvements that have emerged in the past 30 years.


Pharmaceutical Technology


Without packaging, it would be virtually impossible to deliver pharmaceutical products to patients. Packaging helps protect, contain, carry, dispense, and sell pharmaceuticals. It also helps drug manufacturers educate and motivate consumers.


Barrier packaging increasingly relies on new materials or combinations of materials. For maximum protection of moisture-sensitive pharmaceuticals, Alcan Packaging Singen GmbH (Singen, Germany) incorporates a desiccant in the seal layer of its "Formpack with Desiccant" foil laminate.
Over the years, pharmaceutical packaging has experienced many changes. Innovations have come in four categories: design, materials and containers, equipment, and logistics. Some advances involve more than one category.

Advances in design

Innovations in package design perform many functions. They prevent children from unwittingly taking dangerous doses of medication, improve seniors' access to pharmaceuticals, protect consumers from malicious tampering, reduce medication errors, simplify adherence to dosage regimens, and educate consumers about the benefits and risks of drugs.

Before the passage of the Poison Prevention Packaging Act (PPPA) in 1970, an appalling number of toddlers were sickened or died because they accidentally ingested toxic amounts of prescription drugs or aspirin. The PPPA mandated "special packaging" for these products that makes it difficult for a toddler to gain access to a harmful dose. In 1978, iron-containing supplements were added to the list of products that must have child-resistant (CR) packaging. CR packaging concepts include press-and-turn closures, squeeze-and-turn closures, and peel–push blisters.


Milestone. 30 Years of Pharmaceutical Technology
The Consumer Product Safety Commission (CPSC, Washington, DC) credits CR packaging with saving an estimated 700 lives since PPPA took effect (1). The packaging had one major disadvantage, however. Many designs that were difficult for kids to open were hard for senior citizens with limited hand strength and dexterity to open. When CPSC noted a rising number of poisonings because a grandparent transferred his or her medication to a non-CR container or didn't reclose a CR container properly, the commission changed test protocols to ensure that CR packaging was also senior-friendly.

Several senior-friendly designs have been introduced, but there's still room for improvement. According to the CPSC, "Almost one third of oral prescription drugs involved in accidental ingestions by children under five belongs to someone other than the child's immediate family such as grandparents and other older adults" (2).

In addition to preventing childhood poisonings, packaging helps ensure drug products have not been tampered with and are genuine. Tamper-evident (TE) packaging originated in 1982, when seven people died after ingesting poisoned "Tylenol" capsules. The case, which remains unsolved, resulted in regulations that require TE packaging for most over-the-counter (OTC) pharmaceuticals. Options include shrink bands and nonfoam inner seals with a distinctive identifying characteristic, closures with a breakable band, and blister cards. Rules require packaging to carry information about the TE feature so consumers know what to look for.


Pfizer's "Exubera," the world's first inhaled insulin, wouldn't be possible without packaging innovations that contain and dispense the powdered insulin.
In 1986, poisoned "Excedrin" capsules caused more deaths, and packaging rules were changed to require two TE features for all capsule products. These features often entail sealing the capsules themselves and incorporating another feature such as a shrink band.

Counterfeit pharmaceuticals have become a huge problem worldwide as well. In fact, most studies estimate that 10% of drugs in the global supply chain are counterfeit. According to the US Food and Drug Administration (Rockville, MD), "drug products with a high market value or that are high-priced or have high sales volume are more frequently subject to counterfeiting and diversion" (3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here